Toll Free: 1-888-928-9744
Published: Oct, 2014 | Pages:
35 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
N30 Pharmaceuticals - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'N30 Pharmaceuticals - Product Pipeline Review - 2014', provides an overview of the N30 Pharmaceuticals's pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of N30 Pharmaceuticals's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of N30 Pharmaceuticals including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of N30 Pharmaceuticals's human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the N30 Pharmaceuticals's pipeline products Reasons to buy - Evaluate N30 Pharmaceuticals's strategic position with total access to detailed information on its product pipeline - Assess the growth potential of N30 Pharmaceuticals in its therapy areas of focus - Identify new drug targets and therapeutic classes in the N30 Pharmaceuticals's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of N30 Pharmaceuticals and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of N30 Pharmaceuticals - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of N30 Pharmaceuticals and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 N30 Pharmaceuticals Snapshot 5 N30 Pharmaceuticals Overview 5 Key Information 5 Key Facts 5 N30 Pharmaceuticals - Research and Development Overview 6 Key Therapeutic Areas 6 N30 Pharmaceuticals - Pipeline Review 9 Pipeline Products by Stage of Development 9 Pipeline Products - Monotherapy 10 N30 Pharmaceuticals - Pipeline Products Glance 11 N30 Pharmaceuticals - Clinical Stage Pipeline Products 11 Phase II Products/Combination Treatment Modalities 11 Phase I Products/Combination Treatment Modalities 12 N30 Pharmaceuticals - Early Stage Pipeline Products 13 Preclinical Products/Combination Treatment Modalities 13 Discovery Products/Combination Treatment Modalities 14 N30 Pharmaceuticals - Drug Profiles 15 N-6022 15 Product Description 15 Mechanism of Action 15 R&D Progress 15 N-91115 16 Product Description 16 Mechanism of Action 16 R&D Progress 16 N-1785 17 Product Description 17 Mechanism of Action 17 R&D Progress 17 N-1861 18 Product Description 18 Mechanism of Action 18 R&D Progress 18 N-6338 19 Product Description 19 Mechanism of Action 19 R&D Progress 19 N-6547 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 N-91138 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 N-91169 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 N-6000 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 N-9000 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 N30 Pharmaceuticals - Pipeline Analysis 25 N30 Pharmaceuticals - Pipeline Products by Target 25 N30 Pharmaceuticals - Pipeline Products by Route of Administration 26 N30 Pharmaceuticals - Pipeline Products by Molecule Type 27 N30 Pharmaceuticals - Pipeline Products by Mechanism of Action 28 N30 Pharmaceuticals - Recent Pipeline Updates 29 N30 Pharmaceuticals - Dormant Projects 32 N30 Pharmaceuticals - Locations And Subsidiaries 33 Head Office 33 Appendix 34 Methodology 34 Coverage 34 Secondary Research 34 Primary Research 34 Expert Panel Validation 34 Contact Us 35 Disclaimer 35
List of Tables N30 Pharmaceuticals, Key Information 5 N30 Pharmaceuticals, Key Facts 5 N30 Pharmaceuticals - Pipeline by Indication, 2014 8 N30 Pharmaceuticals - Pipeline by Stage of Development, 2014 9 N30 Pharmaceuticals - Monotherapy Products in Pipeline, 2014 10 N30 Pharmaceuticals - Phase II, 2014 11 N30 Pharmaceuticals - Phase I, 2014 12 N30 Pharmaceuticals - Preclinical, 2014 13 N30 Pharmaceuticals - Discovery, 2014 14 N30 Pharmaceuticals - Pipeline by Target, 2014 25 N30 Pharmaceuticals - Pipeline by Route of Administration, 2014 26 N30 Pharmaceuticals - Pipeline by Molecule Type, 2014 27 N30 Pharmaceuticals - Pipeline Products by Mechanism of Action, 2014 28 N30 Pharmaceuticals - Recent Pipeline Updates, 2014 29 N30 Pharmaceuticals - Dormant Developmental Projects,2014 32
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.